SCHEMBL400158

SCHEMBL400158

CC(=O)SCC(Cc1ccc(Br)cc1)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MME P08473 12/20 0.54
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
ABCC3 O15438 1/20 0.45
NR1I2 O75469 1/20 0.45
ABCB11 O95342 1/20 0.45
NR3C1 P04150 1/20 0.45
RARG P13631 1/20 0.45
CNR1 P21554 1/20 0.45
OPRK1 P41145 1/20 0.45
NR1H2 P55055 1/20 0.45
PPARA Q07869 1/20 0.45
NR1H3 Q13133 1/20 0.45
NR1I3 Q14994 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7435690 0.86 CYP1A2 (0.46) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL838962 0.85 CYP1A2 (0.63) MMECYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL838961 0.85 CYP1A2 (0.63) MMECYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL6154521 0.85 CYP1A2 (0.63) MMECYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL7435026 0.84 CYP1A2 (0.45) MMECYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL7325309 0.84 PPARG (0.49) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL6572922 0.84 CYP1A2 (0.61) MMECYP1A2CYP3A4CYP2D6CYP2C9
Hydrochloric Acid SCHEMBL6572923 0.84 CYP1A2 (0.61) MMECYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL7428223 0.83 CYP1A2 (0.44) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL7319468 0.83 CYP1A2 (0.51) MMECYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101665-B2 Process for synthesis of tritiated and deuterated thiorphan and acetorphan ROCHE PALO ALTO LLC (US) 2012-01-24 US disclosed
US-20110319656-A1 PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN ROCHE PALO ALTO LLC 2011-12-29 US disclosed
WO-2009077386-A1 PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
US-6136842-A INHIBITION OF ENDOTHELIN-CONVERTING ENZYME HOECHST MARION ROUSSEL (FR) 2000-10-24 US disclosed
CN-1218467-A Sulphur derivatives comprising amide bond, method for preparing same, use thereof as drugs, and pharmaceutical compositions containing such derivatives HOEST MARION RUSO S A (FR) 1999-06-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319656-A1 PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN NAT1, ZRANB2, TXN MME 17/4885CYP1A2 91/4885CYP3A4 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.